Global Alzheimer’s Platform Foundation Welcomes Chief Commercial Officer Lammert Albers

The Global Alzheimer’s Platform Foundation® adds Lammert Albers to its team in the role of chief commercial officer; he joins GAP with leadership experience in growing clinical trial and life science technology companies

WASHINGTON, DC (Feb. 21, 2023) — The Global Alzheimer’s Platform Foundation (GAP) welcomes Lammert Albers to its leadership team. Lammert has successfully grown a variety of clinical trial and CNS technology companies and will serve as GAP’s first chief commercial officer. He joins GAP from Cytel, a leader in statistical software and advanced analytics for trial design and execution, where he served as global vice president for business development.

“The addition of Lammert to our leadership team will advance our growth and accelerate our  development of next-generation solutions for improving all aspects of clinical research,” said GAP President John Dwyer. “The depth of experience that he brings to GAP will build on the work we’re doing to advance and transform neurodegenerative clinical research to make life better for all of the people who are living with Alzheimer’s and Parkinson’s disease.”

Lammert has more than twenty years of commercial leadership experience supporting top-tier organizations. Early in his career, he worked as an infectious disease bioscientist with AstraZeneca at its UK headquarters. Having made the move away from the laboratory, Lammert led his first sales team at Genaissance Pharmaceuticals, a Nasdaq-listed pharmacogenomics contract research organization. He has also served in leadership positions at ICON, Cogstate and IXICO.

“This is an exciting time to join a team of elite clinical trial professionals that are highly mission-driven,” Lammert said. “I have waited a long time for what now feels like a watershed moment that has arrived in Alzheimer’s disease research, and I look forward to seeing how GAP can accelerate better solutions for researchers and patients as we pursue therapies and cures for this fatal disease.”


For immediate release:


About the Global Alzheimer’s Platform Foundation (GAP)

The nonprofit Global Alzheimer’s Platform Foundation® was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.

To top